PE20020917A1 - Derivados de imidazol como bloqueadores del receptor n-metil-d-aspartato - Google Patents

Derivados de imidazol como bloqueadores del receptor n-metil-d-aspartato

Info

Publication number
PE20020917A1
PE20020917A1 PE2002000055A PE2002000055A PE20020917A1 PE 20020917 A1 PE20020917 A1 PE 20020917A1 PE 2002000055 A PE2002000055 A PE 2002000055A PE 2002000055 A PE2002000055 A PE 2002000055A PE 20020917 A1 PE20020917 A1 PE 20020917A1
Authority
PE
Peru
Prior art keywords
methyl
alkyl
imidazole
imidazol
phenyl
Prior art date
Application number
PE2002000055A
Other languages
English (en)
Inventor
Alexander Alanine
Bernd Buettelmann
Marie-Paule Heitz Neidhart
Georg Jaeschke
Emmanuel Pinard
Rene Wyler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20020917A1 publication Critical patent/PE20020917A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Abstract

SE REFIERE A DERIVADOS DE IMIDAZOL DE FORMULA I DONDE A ES FENILO, PIRIDIN-2-IL, PIRIDIN-3-IL, PIPERIDIN-1-IL; R1 Y R2 SON H, HALOGENO, ALQUILO, CICLOALQUILO, ALQUENILO, TRIFLUOROMETILO, O-TRIFLUOROMETILO, ENTRE OTROS; R3 ES H, ALQUILO, CICLOALQUILO, FENILO, S-ALQUILO, AMINO, ENTRE OTROS; R4 Y R5 SON H, ALQUILO O JUNTO A C FORMAN (CH2)4; R6 Y R6' SON H, ALQUILO; X ES N, C=, Y ES =N, NH, N=CH, CH=; Z ES CR7=, N=, NR7, N=CR7, ENTRE OTROS; R7 ES H, CH2OH, ALQUILO; n ES 0-2; m ES 0-1. SON COMPUESTOS PREFERIDOS 1H-IMIDAZOL, 1-[[1-(4-CLORO-3-METILFENIL)-1H-IMIDAZOL-4-IL]METIL]-2-ETIL; 1H-IMIDAZOL, 1[[1-(4-CLORO-3-METILFENIL)-1H-IMIDAZOL-4-IL]METIL]-2-METIL; 1-(3,4-DICLORO-FENIL)-3-(2-METIL-IMIDAZOL-1-IL-METIL)-1H-PIRAZOL, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS SON BLOQUEADORES ESPECIFICOS DE UN SUBTIPO DE RECEPTOR DE N-METIL-D-ASPARTATO NMDA Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE NEURODEGENERACION, ENFERMEDAD DE ALZHEIMER, PARKINSON, HUNTINGTON, ESCLEROSIS LATERAL AMIOTROFICA, NEURODEGENERACION ASOCIADA CON INFECCIONES BACTERIANAS VIRICAS, DEPRESION
PE2002000055A 2001-01-29 2002-01-24 Derivados de imidazol como bloqueadores del receptor n-metil-d-aspartato PE20020917A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01101947 2001-01-29

Publications (1)

Publication Number Publication Date
PE20020917A1 true PE20020917A1 (es) 2002-10-19

Family

ID=8176317

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000055A PE20020917A1 (es) 2001-01-29 2002-01-24 Derivados de imidazol como bloqueadores del receptor n-metil-d-aspartato

Country Status (24)

Country Link
US (3) US6610723B2 (es)
EP (1) EP1358165B1 (es)
JP (1) JP4094956B2 (es)
KR (1) KR100619106B1 (es)
CN (2) CN1489580B (es)
AR (1) AR035422A1 (es)
AT (1) ATE425147T1 (es)
BR (1) BR0206758A (es)
CA (1) CA2434813C (es)
CY (1) CY1110265T1 (es)
DE (1) DE60231477D1 (es)
DK (1) DK1358165T3 (es)
ES (1) ES2319967T3 (es)
GC (1) GC0000318A (es)
GT (1) GT200200013A (es)
HK (2) HK1063794A1 (es)
JO (1) JO2292B1 (es)
MX (1) MXPA03006773A (es)
MY (1) MY138334A (es)
PA (1) PA8537801A1 (es)
PE (1) PE20020917A1 (es)
PT (1) PT1358165E (es)
WO (1) WO2002060877A1 (es)
ZA (1) ZA200305626B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2485093A1 (en) * 2002-05-02 2003-11-13 Neurogen Corporation Substituted imidazole derivatives: gabaa receptor ligands
WO2005028467A1 (en) 2003-09-15 2005-03-31 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
KR101170925B1 (ko) * 2004-06-18 2012-08-07 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 암 치료용 키네신 방추 단백질 (ｋｓｐ) 억제제로서의ｎ-(1-(1-벤질-4-페닐-1ｈ-이미다졸-2-일)-2,2-디메틸프로필)벤자미드 유도체 및 관련 화합물
ITRM20050094A1 (it) * 2005-03-04 2006-09-05 Univ Siena Derivati del 1-(1,5-di(4-clorofenil)-2metil-1h-3-pirroli)metil)-4-metilpiperazina (bm 212), procedimento per la loro produzione e uso di essi come antitubercolari.
US7939556B2 (en) 2005-10-14 2011-05-10 Neurosearch A/S Imidazole derivatives and their use for modulating the GABAA receptor complex
KR100694181B1 (ko) * 2005-11-25 2007-03-12 연세대학교 산학협력단 근원세포 또는 근섬유로부터 신경세포 분화를 유도하는화합물, 이를 포함하는 약학적 조성물, 신경세포 분화를유도하는 방법 및 신경세포 분화를 유도하는 화합물을검색하는 스크리닝 방법
CA2687973C (en) * 2007-05-23 2015-04-07 Allergan, Inc. ((bicylicheteroaryl) imidazolyl)methylheteroaryl compounds as adrenergic receptor agonists
WO2010009327A1 (en) 2008-07-17 2010-01-21 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compounds for the treatment of pathologies associated with aging and degenerative disorders
KR20110092266A (ko) 2008-08-04 2011-08-17 씨에이치디아이 파운데이션, 인코포레이티드 소정 키누레닌-3-모노옥시게나아제 억제제, 약학적 조성물, 및 그의 사용 방법
MX2012008346A (es) 2010-01-25 2012-11-12 Chdi Foundation Inc Determinados inhibidores de cinurenina-3-monooxigenasa, composiciones farmceuticas y metodos de uso de los mismos.
US8993743B2 (en) 2010-02-18 2015-03-31 B.R.A.I.N. Biotechnology Research And Information Network Ag Chimeric surface active proteins
JP2013540145A (ja) * 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス コルチゾール依存性疾患の治療用の選択的ｃｙｐ１１ｂ１阻害剤
CN106518845B (zh) 2011-08-30 2019-09-13 Chdi基金会股份有限公司 犬尿氨酸-3-单加氧酶抑制剂、药物组合物及其使用方法
BR112014004845A2 (pt) 2011-08-30 2017-04-04 Chdi Foundation Inc pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
JP6105594B2 (ja) * 2011-09-30 2017-03-29 エンドゥ ファーマシューティカルズ，インコーポレイティド 癌処置用ｃｙｐ１７阻害剤としてのイミダゾール誘導体
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
SG11201700341PA (en) 2014-07-17 2017-02-27 Chdi Foundation Inc Methods and compositions for treating hiv-related disorders
JP6618525B2 (ja) * 2014-08-15 2019-12-11 ヤンセン ファーマシューティカルズ，インコーポレーテッド ピラゾール類
DK3180329T3 (da) * 2014-08-15 2020-04-06 Janssen Pharmaceuticals Inc Triazoler som nr2b receptorinhibitorer
SG11201806750WA (en) 2016-02-10 2018-09-27 Janssen Pharmaceutica Nv Substituted 1,2,3-triazoles as nr2b-selective nmda modulators
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
US11447503B2 (en) 2019-06-14 2022-09-20 Janssen Pharmaceutica Nv Pyridine carbamates and their use as GLUN2B receptor modulators
IL277071B1 (en) 2018-03-08 2024-03-01 Incyte Corp Aminopyrizine diol compounds as PI3K–y inhibitors
MA52244A (fr) 2018-04-04 2021-02-17 Janssen Pharmaceutica Nv Pyridine et pyrimidines substituées et leur utilisation en tant que modulateurs du récepteur glun2b
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
EP3982958A1 (en) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
EP3983073A1 (en) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Substituted pyrazolo[4,3-b]pyridines and their use as glun2b receptor modulators
KR20220020915A (ko) 2019-06-14 2022-02-21 얀센 파마슈티카 엔.브이. GluN2B 수용체 조절제로서의 피라진 카르바메이트 및 이들의 용도
CN114008052A (zh) 2019-06-14 2022-02-01 詹森药业有限公司 取代的吡唑并-吡嗪以及它们作为GluN2B受体调节剂的用途
PE20220386A1 (es) 2019-06-14 2022-03-18 Janssen Pharmaceutica Nv Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3627155A1 (de) 1986-08-11 1988-02-18 Schering Ag Imidazol-derivate
CN1040107C (zh) * 1993-01-02 1998-10-07 山道士有限公司 咪唑基甲基吡啶
US5872136A (en) * 1996-04-03 1999-02-16 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
US5998424A (en) * 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
DE19816880A1 (de) 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Neue Diphenyl-substituierte 5-Ring-Heterocyclen, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
DE60007697T2 (de) 1999-07-21 2004-12-09 F. Hoffmann-La Roche Ag Triazolderivate

Also Published As

Publication number Publication date
US6610723B2 (en) 2003-08-26
HK1063794A1 (en) 2005-01-14
CN101798298B (zh) 2013-01-09
US20020151715A1 (en) 2002-10-17
JO2292B1 (en) 2005-09-12
EP1358165A1 (en) 2003-11-05
JP2004523535A (ja) 2004-08-05
HK1146646A1 (en) 2011-06-24
JP4094956B2 (ja) 2008-06-04
CY1110265T1 (el) 2015-01-14
US6683097B2 (en) 2004-01-27
GC0000318A (en) 2006-11-01
ZA200305626B (en) 2004-10-21
MY138334A (en) 2009-05-29
MXPA03006773A (es) 2003-10-24
ES2319967T3 (es) 2009-05-18
EP1358165B1 (en) 2009-03-11
CA2434813C (en) 2009-12-22
US20030187268A1 (en) 2003-10-02
ATE425147T1 (de) 2009-03-15
AR035422A1 (es) 2004-05-26
KR20030070615A (ko) 2003-08-30
CN101798298A (zh) 2010-08-11
US20030191311A1 (en) 2003-10-09
WO2002060877A1 (en) 2002-08-08
PA8537801A1 (es) 2002-09-17
DE60231477D1 (en) 2009-04-23
GT200200013A (es) 2002-09-02
BR0206758A (pt) 2004-02-17
CN1489580A (zh) 2004-04-14
CN1489580B (zh) 2010-05-26
CA2434813A1 (en) 2002-08-08
DK1358165T3 (da) 2009-05-11
US6667335B2 (en) 2003-12-23
PT1358165E (pt) 2009-04-22
KR100619106B1 (ko) 2006-09-01

Similar Documents

Publication Publication Date Title
PE20020917A1 (es) Derivados de imidazol como bloqueadores del receptor n-metil-d-aspartato
EA200301215A1 (ru) Лиганды рецепторов 5-ht и их применение
MXPA04006003A (es) Derivados del acido fenilpropionico substituidos como agonistas al receptor alfa activado-proliferativo de peroxisoma (ppar) humano.
PE20020506A1 (es) Derivados de pirazol fusionados como inhibidores de la proteina cinasa
HUP0402236A2 (hu) Heterociklusos vegyületek, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
RS51963B (en) 4- (2-AMINO-1-HYDROXYETHYL) PHENOL DERIVATIVES AS AGONISTS OF BETA-2 ADRENERGIC RECEPTORS
PE86398A1 (es) Derivados de la 4-hidroxi-piperidina
ATE390922T1 (de) 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
MA28422B1 (fr) Derives de n- (1,5-diphenyl-1h-pyrazol-3-yl) sulfonamide avec une affinite pour les recepteurs cb1
RU2004104625A (ru) Аналоги простагландинов в качестве агонистов рецептора ep4
EA200700047A1 (ru) Новые алкильные производные в качестве метаботропных рецепторов глутамата
AR036115A1 (es) Compuesto de n-aroilaminas, composiciones farmaceuticas formuladas con dichos compuestos; uso de los compuestos mencionados en la preparacion de composiciones farmaceuticas para tratar,prevenir enfermedades o trastornos donde se requiere la aplicacion de antagonistas de receptores de la orexina huma
PE20081783A1 (es) Nuevas 2-aminooxazolinas como ligandos de taar1
JP2013538801A5 (es)
PE20050420A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
KR970706259A (ko) 도파민 수용체 아류형 특이적 리간드로서 아미노메틸 페닐 이미다졸 유도체(certain aminomethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands)
PE20081315A1 (es) Derivados de benzimidazol como antagonistas de vr-1
CA2383779A1 (en) N-(indolecarbonyl)piperazine derivatives
PE20070355A1 (es) Antagonistas de cgrp seleccionados y procedimientos para su preparacion
PE20041061A1 (es) Imidazol-4-il-etinil-piridina
PE20090592A1 (es) Nuevos derivados de piperazina-amida
ATE306488T1 (de) Benzimidazol-verbindungen zur verwendung als orl1-rezeptor-antagonisten
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
PE20001084A1 (es) Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas
PE20091431A1 (es) Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed